Life Biosciences

}}

}}

'''Life Biosciences''' is a [[Boston]] based biopharmaceutical company focused on developing epigenetic medicines for aging and age-related diseases. The company was founded in 2017 by [[Harvard Medical School]] professor David Sinclair. In early 2026, the US [[Food and Drug Administration]] cleared Life Biosciences to begin testing its invesitgational, [[adeno-associated virus|adeno-associated viral]] vector drug, ER-100, for treatment of [[optic neuropathy|optic neuropathies]] including certain types of [[glaucoma]] and [[non-arteritic anterior ischemic optic neuropathy]]. The drug is proposed to work by expressing [[Yamanaka factors]] to alter [[DNA methylation]] states.{{cite news |last=Quiroz-Gutierrez|first=Marco|date=30 January 2026|title=As billionaires chase immortality, this startup cofounded by a Harvard genetics professor gets FDA approval for the first partial de-aging human trial|url=https://fortune.com/2026/01/30/billionaires-longevity-aging-fda-human-clinical-trial-life-biosciences-jerry-mclaughlin-david-sinclair-harvard-science/|work=[[Fortune]]|location= |publisher= |access-date=19 March 2026}}{{cite news |last=McMahon|first=Raphael|date=30 October 2025|title=This Longevity Startup Is Bringing Anti-Aging Gene Therapy to Human Trials|url=https://observer.com/2025/10/this-longevity-startup-is-bringing-anti-aging-gene-therapy-to-human-trials/|work=[[The New York Observer]]|location= |publisher= |access-date=19 March 2026}}{{cite news |last=Weisman|first=Robert|date=1 December 2018|title=Fountains of youth: Biotech startups emerge from stealth mode to ‘take on aging’|url=https://www.bostonglobe.com/metro/2018/12/01/fountains-youth-biotech-startups-emerge-from-stealth-mode-take-aging/qTXKvfu3uJLoMxteLI7HxM/story.html|work=[[Boston Globe]]|location= |publisher= |access-date=19 March 2026}}{{cite journal |last1= |first1= |last2= |first2= |date=17 February 2026|title=FDA go-ahead to test cellular rejuvenation therapy in humans|url=https://www.nature.com/articles/s41587-026-03037-z|journal=[[Nature (journal)]]|volume= |issue= |publisher= |pages= |doi=10.1038/s41587-026-03037-z|access-date=19 March 2026|url-access= subscription}}

'''Life Biosciences''' is a [[Boston]] based biopharmaceutical company focused on developing epigenetic medicines for aging and age-related diseases. The company was founded in 2017 by [[Harvard Medical School]] professor David Sinclair. In early 2026, the US [[Food and Drug Administration]] cleared Life Biosciences to begin testing its invesitgational, [[adeno-associated virus|adeno-associated viral]] vector drug, ER-100, for treatment of [[optic neuropathy|optic neuropathies]] including certain types of [[glaucoma]] and [[non-arteritic anterior ischemic optic neuropathy]]. The drug is proposed to work by expressing [[Yamanaka factors]] to alter [[DNA methylation]] states.{{cite news |last=Quiroz-Gutierrez|first=Marco|date=30 January 2026|title=As billionaires chase immortality, this startup cofounded by a Harvard genetics professor gets FDA approval for the first partial de-aging human trial|url=https://fortune.com/2026/01/30/billionaires-longevity-aging-fda-human-clinical-trial-life-biosciences-jerry-mclaughlin-david-sinclair-harvard-science/|work=[[Fortune (magazine)|Fortune]]|location= |publisher= |access-date=19 March 2026}}{{cite news |last=McMahon|first=Raphael|date=30 October 2025|title=This Longevity Startup Is Bringing Anti-Aging Gene Therapy to Human Trials|url=https://observer.com/2025/10/this-longevity-startup-is-bringing-anti-aging-gene-therapy-to-human-trials/|work=[[The New York Observer]]|location= |publisher= |access-date=19 March 2026}}{{cite news |last=Weisman|first=Robert|date=1 December 2018|title=Fountains of youth: Biotech startups emerge from stealth mode to ‘take on aging’|url=https://www.bostonglobe.com/metro/2018/12/01/fountains-youth-biotech-startups-emerge-from-stealth-mode-take-aging/qTXKvfu3uJLoMxteLI7HxM/story.html|work=[[Boston Globe]]|location= |publisher= |access-date=19 March 2026}}{{cite journal |last1= |first1= |last2= |first2= |date=17 February 2026|title=FDA go-ahead to test cellular rejuvenation therapy in humans|url=https://www.nature.com/articles/s41587-026-03037-z|journal=[[Nature (journal)]]|volume= |issue= |publisher= |pages= |doi=10.1038/s41587-026-03037-z|access-date=19 March 2026|url-access= subscription}}

==References==

==References==